Illingworth Group Ltd
Illingworth Research is a full service clinical CRO with experience across all phases of development from Phase I / proof of concept studies to post-marketing studies for small molecules, biotechnology products, medical devices and diagnostics. With a network of clinical infrastructure covering most therapeutic areas varying from clinical research units, primary, secondary and tertiary care sites across Europe and with partners in North America and Australasia, Illingworth has the capability to deliver large multi-centre global studies on time and within budget. Illingworth also provides research nurses for patient homecare to support studies for optimisation of patient retention and compliance. Illingworth also offers a medical photography service.
Invicro, a leading global provider of imaging-based service solutions and image analysis software for research and drug development, was founded with a mission of improving the value of imaging in drug discovery and development. Invicro’s 250-person team provides a full range of imaging services and software solutions including contract imaging, research and clinical trial management services, custom data analysis, and software programs for image data management, visualization and high-throughput processing.
J A Kemp
We are one of the largest UK and European Patent and Trade Mark Attorney firms, with offices in London, Oxford, Cambridge and Munich. The breadth and depth of our technical knowledge relevant to patents is outstanding, with over 70 science and technology graduates in the firm including over 30 PhDs. No area of science or technology is outside our scope.
Masters Speciality Pharma
Founded over 30 years ago, Masters Speciality Pharma is an international pharmaceutical company specialising in the distribution of unlicensed medicinal products to Physicians, Hospitals, Clinics, Government institutions and individual patients, providing access to essential life-saving treatments worldwide.
Masters is fully compliant with regulatory requirements in all jurisdictions enabling us to deliver tailored medical solutions to over 90 countries worldwide, and is trusted as a reliable source of pharmaceutical product
Medherant is a leading developer of next-generation transdermal drug delivery patches.
Transdermal delivery of drugs from a patch provides better control of the dose than achieved with gels, ointments and creams. However, the currently available technologies limit the types of drugs that can be used and the quantities that can be loaded into the patch. Medherant’s TEPI Patch® is formulated with a novel polymer adhesive that is mixed with the drug.
One of the key advantages of the TEPI Patch® technology is that a greater quantity of drug can be blended with the adhesive. This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch. The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove.
Medherant is developing its own TEPI Patch® products and working with third parties to assess the suitability of the technology for their drugs.
The Company expects to earn revenues from licensing both its products and its technology for use with specific drugs.
MediWales is the life science network and representative body for Wales. An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.
MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally.